Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Management View Chad Robins, Co-Founder, CEO & Chairman, highlighted ...
Seeking Alpha

GeneDx: Strong Testing Volume And An Invaluable Genomic Database

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow ...
StockStory.org on MSN

LH Q4 deep dive: Specialty testing and hospital partnerships offset volume challenges

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to ...

CareDx outlines $420M-$444M 2026 revenue target amid solution selling and cell therapy pipeline expansion

CareDx expects full year 2026 revenue of $420 million to $444 million. Testing Services revenue is projected at $306 million to $326 million, with total testing volume of 220,000 to 228,000 tests. The ...
Insider Monkey

Accelerated Testing Volume Lifted CareDx (CDNA) in Q3

Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund ...